HONG KONG May 24 WuXi Biologics (Cayman) Inc, a
Chinese contract drug research and development company, plans to
launch on Thursday an initial public offering of up to $513
million in Hong Kong, IFR reported, citing people close to the
The company is offering 193 million shares in an indicative
range of HK$18.60 to HK$20.60 each, valuing the total deal at up
to HK$3.98 billion, the Thomson Reuters publication added.
WuXi Biologics, which does work for pharmaceutical and
biotechnology firms, did not immediately respond to a Reuters
request for comment.
Bank of America Merrill Lynch, China Merchants Securities
and Morgan Stanley are joint sponsors of the IPO, the listing
($1=7.7891 Hong Kong dollars)
(Reporting by Fiona Lau of IFR; Writing by Elzio Barreto;
Editing by Clarence Fernandez)